Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRISPR-Cas9 PD-1 KO Mesothelin CAR-T in Solid Tumors
NCT03747965Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-mesothelin CAR T-cells (Chinese PLA General Hospital) in pancreatic cancer (PC), cholangiocarcinoma (CCA), ovarian cancer and 1 more, sponsored by Chinese PLA General Hospital. Primary endpoint: Study of related adverse events at 24 weeks. Status: unknown.
02
Drugs
anti-mesothelin CAR T-cells (Chinese PLA General Hospital)
03
Conditions
pancreatic cancer (PC)cholangiocarcinoma (CCA)ovarian cancersolid tumor
Beyond the preview
Go deeper on NCT03747965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747965.